ASIATICLAB Asiatic Laboratories Limited
Pharmaceuticals & Chemicals
Tk 107.3 as of 2026-11-12 14:09:18
Data completeness 100%
Score breakdown
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Solvency Low debt: debt/equity 0.19x (below 0.5)
Concerns
- Profitability Average ROE only 4.09% (below 10%: capital not working hard)
- Profitability Net profit shrinking 1.67% a year
- Valuation P/E 22.93 is high (above 20)
- Valuation Price is 37% above the Graham fair value (Tk 78.3)
Notes
- Consistency EPS rose in 1 of 3 years (mixed)
Risk flags
No flags raised.
Valuation
52-week range
142.8% above the low, 27% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
Dividends and safety
Size, liquidity and ownership
Shareholding
- Sponsor/director 40.7%
- Institution 13.7%
- Public 45.6%
Audited history
| Year | EPS (Tk) | NAV/share | Net profit (cr) | Cash div % | Bonus % |
|---|---|---|---|---|---|
| 2022 | 3.06 | 59.68 | 27 | — | — |
| 2023 | 2.19 | 64.48 | 21 | — | — |
| 2024 | 2.82 | 52.58 | 28 | 10 | 0 |
| 2025 | 2.09 | 54.08 | 26 | 10 | 0 |
Fiscal year ends June. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 10.4%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.